Market Overview

Why Shares Of Micro-Cap Biotech Akari Therapeutics Are Ripping Higher

Share:
Why Shares Of Micro-Cap Biotech Akari Therapeutics Are Ripping Higher

The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ: AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on above-average volume.

What Happened

Akari, which focuses on developing therapies for orphan autoimmune and inflammatory diseases, said Wednesday the FDA has granted its nomacopan Fast Track designation for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA, in pediatric patients.

Why It's Important

HSCT-TMA is an orphan condition with no approved therapy and and an estimated fatality rate of 80%.

The Fast Track designation is issued to facilitate the development and expedite the review of new drugs that show promise in treating serious life-threatening conditions and address unmet medical needs.

The status vests advantages such as frequent communication and meetings with the FDA to review the developmental plan for the drug, including the design of proposed clinical trials, use of biomarkers and the extent of data needed for approval.

If relevant criteria are met, a drug with a Fast Track designation qualifies for a priority review, which reduces the review period from the standard 12 months to six months.

The pivotal trial that could support a regulatory filing is set to commence in the fourth quarter of 2019.

Akari shares were trading higher by 34.25% at $2.43 at the time of publication Wednesday on about 150 times their average volume. 

Related Links:

The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study

Posted-In: Biotech News FDA Movers Trading Ideas General Best of Benzinga

 

Related Articles (AKTX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

These Traders Would Stay Away From McDonald's For Now

Analyst: New UPS CFO Brings Outsider Perspective